Kessler scientists monitor Ekso device in six patients with traumatic SCI

NewsGuard 100/100 Score

Results encourage researchers planning clinical study for rehabilitation

Monitored by scientists at Kessler Foundation, six people with traumatic spinal cord injuries tested Ekso, the robotic exoskeleton from Ekso Bionics that enables wheelchair users to stand and walk. The six participated in one week of preliminary testing in October 2011. Five patients have paraplegia and one has quadriplegia; they ranged in age from 27 to 45 and had durations of injury from 4 months to 2 years. This video highlights their experiences: https://www.youtube.com/user/KesslerFoundation#p/u/0/HcSEL4FDAVs

In early 2012, the research team, headed by senior research scientist Gail Forrest, PhD, will commence a clinical study in collaboration with Kessler Institute for Rehabilitation.

The week of preliminary testing provided key information that will guide protocol development, including selection criteria for individuals with spinal cord injury. "We will look at the effects of standing and walking for people with paralysis due to spinal cord injury," said Dr. Forrest. "Whether there are physiologic changes taking place, and what those changes mean in terms of functional improvement." While the study at Kessler will focus on the benefits of Ekso in rehabilitation settings, Ekso Bionics also plans to explore the potential for home and community use.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer